ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

A new study by Indiana University School of Medicine researchers has revealed a breakthrough in the fight against acute myeloid leukemia, one of the most aggressive and fatal blood cancers in adults.

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, ...

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

A watercolor set gifted during my bone marrow transplant for acute myeloid leukemia became my outlet for wonder, creativity, ...

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Scientists at Indiana University School of Medicine have identified a new approach that could transform treatment for acute ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

Of 34 CMML treatment-naïve participants enrolled and treated with lenzilumab plus azacitidine, 22 have evaluable responses in the first twelve months of follow-up - Building upon previously reported ...

Caregivers play crucial roles in the lives of people with acute myeloid leukemia (AML). But the caregiving responsibilities can get overwhelming and stressful at times. Learn more about how to ...